FDA Permits Marketing Of First Game-Based Digital Therapeutic To Improve Attention Function In Children With ADHD

The U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital therapeutic device to improve attention function in children with attention deficit hyperactivity disorder (ADHD). The prescription-only game-based device, called EndeavorRx, is indicated for children ages 8 to 12 years old with primarily inattentive or combined-type ADHD who have demonstrated an attention issue.

EndeavorRx is indicated to improve attention function as measured by computer-based testing and is the first digital therapeutic intended to improve symptoms associated with ADHD, as well as the first game-based therapeutic granted marketing authorization by the . . .